EUCTR2005-001824-35-GB进行中(未招募)1 期
on-randomised phase II trial of Sequential Therapy of Imiquimod followed by Vaccination with TA CIN for High Grade VI
niversity of Manchester0 个研究点目标入组 30 人开始时间: 2005年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Aged 18-70
- •Non-child bearing or using effective contraception
- •Patients with VIN3 or AIN3, histologically confirmed by biopsy within the previous 3 months
- •Given written informed consent
- •Patients must have at least one lesion of sufficient size to allow biopsies to be taken on 3 occasions and for disease evaluation to be performed. (It is estimated that a lesion of approximately 1 cm diameter would be sufficient.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any patient who has received active treatment for VIN3 or AIN3 in the previous 4 weeks prior to enrolment.
- •Any patient with VAIN3 requiring treatment
- •Any patient who has received an HPV vaccine in the past
- •Known immunodeficiency, defined as:
- •Active eczema in the last 12 months
- •Any patient who is pregnant, planning pregnancy, or breast feeding
- •Any patient receiving immunosuppressive therapy
- •Any patient with clinically significant abnormal serum biochemistry, haematology or urinanalysis
- •Any patient with evidence of an ongoing infection
- •History of severe allergy including eczema or other exfoliative skin disorder or active skin diseases such as psoriasis, lichen planus or sepsis among patients or among close social, sexual or domestic contacts
- •History of severe adverse reaction to any vaccine
- •Receipt of blood or blood products in the last 3 months
- •Women whose last cervical smear was abnormal. If their last smear was more than 3 years ago, it must be repeated at screening
- •Any patient who either has ano-genital carcinoma or who, in the investigator’s opinion, is at high risk of developing ano-genital carcinoma over the next 6 months
研究者
相似试验
进行中(未招募)
1 期
Phase II clinical trial of palliativ treatment of patients with advanced non-operable gastric carcinoma: FLOT regimen followed by AIO regimen and irinotecan combined with artificial nutrition and physical activity - impact on quality of life and fatigue: FLOTIRI gastric cancer trialAdvanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junctionMedDRA version: 15.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014895-23-DEniversitätsklinikum Erlangen50
尚未招募
不适用
Randomized Phase II study regarding treatment cycles of neo-adjuvant chemotherapy with biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancerResectable Biliary Tract CancersJPRN-UMIN000036542KHBO100
进行中(未招募)
不适用
Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patientsMETASTATIC BREAST CANCERMedDRA version: 7.0Level: LLTClassification code 10027475EUCTR2004-002759-15-ESDr. Miguel Martín
进行中(未招募)
1 期
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)EUCTR2016-004452-29-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS70
招募中
1 期
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)MedDRA version: 26.1Level: LLTClassification code: 10001198Term: Adenocarcinoma of the prostate metastatic Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2024-511660-89-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.70
